EyeGate Pharmaceuticals, Inc. Garners $15,000,000 Series C Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1aa82887-8d38-4777-8df7-63de12c45cb2&Preview=1 -
Date
3/12/2008 -
Company Name
EyeGate Pharmaceuticals, Inc. -
Mailing Address
100 Beaver Street Waltham, MA 02453 -
Company Description
EyeGate Pharma is focused on replacing ocular injections and other invasive methods of ocular disease treatment. Our goal is to build a pipeline of safer, more effective and patient friendly ocular treatments based on our EyeGate® II Delivery System. -
Website
http://www.eyegatepharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$15,000,000 -
Transaction Round
Series C -
Proceeds Purposes
Stephen From, President and Chief Executive Officer of EyeGate Pharma, commented, “Withthis venture financing, EyeGate will enter into two Phase II clinical studies utilizing theEyeGate II Delivery System and a proprietary formulation of a corticosteroid. In the first half of2008 we will initiate a Phase II trial in severe uveitis, and in the second half of the year we willinitiate a Phase II trial in dry eye. EyeGate is well on its way to becoming a leader inophthalmic drug development and the delivery partner of choice for ophthalmic drugdevelopers.” -
M&A Terms
-
Venture Investor
Medicis Capital -
Venture Investor
Ventech -
Venture Investor
Undisclosed
